- Home
- RPRX vs DXCM Comparison
RPRX vs DXCM Comparison
Compare RPRX & DXCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPRX | DXCM |
|---|---|---|
| Founded | 1996 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9B | 28.9B |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | RPRX | DXCM |
|---|---|---|
| Price | $57.48 | $86.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 21 |
| Target Price | $51.40 | ★ $85.33 |
| AVG Volume (30 Days) | 2.6M | ★ 4.9M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | N/A | ★ 47.18 |
| EPS | 0.67 | ★ 1.15 |
| Revenue | ★ $2,378,193,000.00 | N/A |
| Revenue This Year | $38.63 | $14.46 |
| Revenue Next Year | $4.73 | $12.31 |
| P/E Ratio | $85.33 | ★ $75.92 |
| Revenue Growth | ★ 5.06 | N/A |
| 52 Week Low | $34.63 | $54.11 |
| 52 Week High | $60.44 | $87.63 |
Technical Indicators
Market Signals| Indicator | RPRX | DXCM |
|---|---|---|
| Relative Strength Index (RSI) | 52.10 | 72.74 |
| Support Level | $54.95 | $62.65 |
| Resistance Level | $58.84 | N/A |
| Average True Range (ATR) | 1.30 | 2.86 |
| MACD | -0.21 | 1.39 |
| Stochastic Oscillator | 37.99 | 97.40 |
Price Performance
Historical ComparisonAbout RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About DXCM DexCom Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.